Effectiveness and cost-effectiveness of antidepressants in primary care: A multiple treatment comparison meta-analysis and cost-effectiveness model

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ramsberg, Joakim ^a   Asseburg, Christian ^b   Henriksson, Martin ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Esior Oy   (Finland)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOSULEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HUMAN; META ANALYSIS; MODEL; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REMISSION;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; HUMANS; MODELS, ECONOMIC; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 84864428375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042003     Document Type: Article

References (30)

1. SBU (2004) Behandling av depressionssjukdomar, volym 1. En systematisk litteraturöversikt. Stockholm, Sweden: Statens beredning för medicinsk utvärdering (SBU). 166/1 166/1.
2. NICE (2010) Depression: The NICE guideline on the treatment and management of depression in adults. National Collaborating Centre for Mental Health for the National Institute for Health & Clinical Excellence. 90 90.
3. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, ((2001)) Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46 (Suppl 1): 38S--58S.
4. Barbui C, Butler R, Cipriani A, Geddes J, Hatcher S, ((2007)) Depression in adults: drug and physical treatments. Clin Evid (Online) 2007.
5. Hansen R, Gartlehner G, Lohr K, Gaynes B, Carey T, ((2005)) Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder. Annals of Internal Medicine 143:: 415--426.
6. Nasjonalt Kunnskapssenter for Helsetjenesten, ((2007)) Effekt og sikkerhet for SSRI og andre nyere antidepressive legemidler ved depresjon hos voksne. 17-2007 17-2007.
7. Sobocki P, Jonsson B, Angst J, Rehnberg C, ((2006)) Cost of depression in Europe. J Ment Health Policy Econ 9:: 87--98.
8. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, et al. ((2009)) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:: 746--758.
9. Keller MB, ((2003)) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:: 3152--3160.
10. Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B, ((2006)) The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 60:: 791--798.
11. National Board of Health and Welfare ((2010)) Nationella riktlinjer för vård vid depression och ångestsyndrom. Stockholm.
12. Machado M, Iskedjian M, Ruiz I, Einarson TR, ((2006)) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 22:: 1825--1837.
13. Normand SL, ((1999)) Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18:: 321--359.
14. Sutton A, Ades AE, Cooper N, Abrams K, ((2008)) Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26:: 753--767.
15. Lunn DJ, Thomas A, Best N, Spiegelhalter D, ((2000)) WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 10:: 325--337.
16. Dias S, Welton NJ, Caldwell DM, Ades AE, ((2010)) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:: 932--944.
17. Gilchrist G, Gunn J, ((2007)) Observational studies of depression in primary care: what do we know? BMC Fam Pract 8:: 28.
18. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, et al. ((2006)) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:: 1231--1242.
19. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, et al. ((2006)) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163: 1519-1530; quiz 1665.
20. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, et al. ((2006)) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163: 1531-1541; quiz 1666.
21. Khan A, Khan SR, Leventhal RM, Brown WA, ((2001)) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 4:: 113--118.
22. von Knorring L, Akerblad AC, Bengtsson F, Carlsson A, Ekselius L, ((2006)) Cost of depression: effect of adherence and treatment response. Eur Psychiatry 21:: 349--354.
23. Löthgren M, Hemels M, François C, Jönsson B, ((2004)) A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary Care Psychiatry 9:: 153--162.
24. Runeson B, Wasserman D, ((1994)) Management of suicide attempters: what are the routines and the costs? Acta Psychiatr Scand 90:: 222--228.
25. Guze SB, Robins E, ((1970)) Suicide and primary affective disorders. Br J Psychiatry 117:: 437--438.
26. Wulsin LR, Vaillant GE, Wells VE, ((1999)) A systematic review of the mortality of depression. Psychosom Med 61:: 6--17.
27. Nierenberg AA, Gray SM, Grandin LD, ((2001)) Mood disorders and suicide. J Clin Psychiatry 62 (Suppl 25): 27--30.
28. Claxton K, ((2008)) Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 26:: 781--798.
29. Melander H, ((2009)) [Meta-analyses uncertain basis for first choice antidepressive agents]. Lakartidningen 106:: 1030--1031.
30. Omori IM, Watanabe N, Nakagawa A, Akechi T, Cipriani A, et al. ((2008)) Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J Psychopharmacol.